Relmada reports FY2024 net loss $80M; cash $44.8M; new Phase 2 programs NDV-01 and sepranolone

RELMADA THERAPEUTICS, INC.

Q4 2024 net loss $18.6M ($0.62/sh) vs $25.1M ($0.84/sh) in Q4 2023; FY2024 net loss $80M ($2.65/sh) vs $98.8M ($3.28/sh).
Cash and short-term investments $44.9M at Dec 31, 2024, down from $96.3M at Dec 31, 2023; runway into H1 2026 based on plans.
Topline Phase 2 data for NDV-01 (bladder cancer) expected at AUA April 26-29, 2025; Phase 2b-ready sepranolone for Tourette syndrome.
Re-evaluating further development of REL-P11 due to competitive landscape in metabolic disease.
R&D expense FY2024 $46.2M, down from $54.8M; G&A $37.7M vs $48.9M, reflecting cost-saving measures.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.